1999～2003：武汉大学药学院药学系，获学士学位；

　　2003～2006：武汉大学药学院药剂系，获硕士学位；

　　2006～2009：北京大学药学院药剂学专业，获博士学位

2009～2012：北京大学基础医学院，博士后； 　　2012～今，北京大学药学院药剂学系，助理研究员

承担2项国家自然科学基金金项目和1项国家“十二五”重大专项课题国家级科研项目，经费累计超过480万；参加了包括国家重点研发计划项目课题、国家科技重大专项、国家自然科学基金重大项目和面上项目在内的多项课题

1. Wenbing Dai, Xiaoyou Wang, Ge Song, Tongzhou Liu, Bing He, Hua Zhang, Xueqing Wang, Qiang Zhang*. Combination antitumor therapy with targeted dual-nanomedicines. Adv Drug Deliv Rev . 2017, 115, 23-45.

2. Binlong Chen, Wenbing Dai*, Bing He, Hua Zhang, Xueqing Wang, Yiguang Wang, Qiang Zhang*. Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment. Theranostics . 2017, 7(3): 538-58.

3. Wenbing Dai#, Fang Yang#, Ling Ma, Yuchen Fan, Bing He, Qihua He, Xueqing Wang, Hua Zhang, Qiang Zhang*. Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer. Biomaterials , 2014, 35(20):5347-5358.

4. Binlong Chen#, Wenbing Dai#*, Dong Mei, Tongzhou Liu, Suxin Li, Bo He, Bing He, Lan Yuan, Hua Zhang, Xueqing Wang, Qiang Zhang*. Comprehensively priming the tumor microenvironment by cancer-associated fibroblast-targeted liposomes for combined therapy with cancer cell-targeted chemotherapeutic drug delivery system. J Control Release . 2016, 241(10): 68-80.

5. Zhiqiang Lin, Dong Mei, Meiwan Chen, Yitao Wang, Xianhui Chen, Zhaoyang Wang,Bing He, Hua Zhang, Xueqing Wang, Wenbing Dai*, Yuxin Yin*, Qiang Zhang*. A comparative study of thermo-sensitive hydrogels with water-insoluble paclitaxel in molecule, nanocrystal and microcrystal dispersions. Nanoscale . 2015, 7(36): 14838-47.

6. Binlong Chen, Zhaoyang Wang, Jing Sun, Qin Song, Bing He, Hua Zhang, Xueqing Wang, Wenbing Dai*, Qiang Zhang*. A tenascin C targeted nanoliposome with navitoclax for specifically eradicating of cancer-associated fibroblasts. Nanomedicine . 2016, 12(1): 131-41.

获得1项美国专利授权和在7项中国专利授权，其中2项已完成专利许可或技术转让